Regulatory clearance for Alere flu test


Via its 510k process, the FDA approves Alere's (ALR +1.9%) i Influenza A&B diagnostic test, the only molecular test that can detect and differentiate the influenza A and B virus in less than 15 minutes. The product was launched in Europe earlier this year.

The firm has rapid molecular tests in development for Strep A, C. difficile, RSV and chlamyida/gonorrhea.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs